Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia.
Obes Res Clin Pract. 2013 May-Jun;7(3):e173-81. doi: 10.1016/j.orcp.2011.11.001.
Obesity is associated with elevated levels of inflammation and metabolic abnormalities, with increased risk of developing insulin resistance, type 2 diabetes, stroke and CVD. Nutrients that can assist in weight loss may also reduce the risk of obesity related co-morbidities.
The aim of this study was to investigate whether LCn-3PUFA, combined with a reduced energy diet, facilitated weight loss and improvements in blood lipids and inflammatory mediators.
A double blind randomised controlled trial with two parallel groups. Both groups followed a low energy diet for 12 weeks, one group consumed 6 × 1 g capsules/d monounsaturated oil (Placebo) (n = 18), the other 6 × 1 g capsules/d LCn-3PUFA (fish oil) (n = 17). Fasting blood samples, anthropometric measurements and 3-day food diaries were collected at baseline and post intervention.
There was a two-fold increase in plasma levels of EPA and DHA in the fish oil group (p < 0.001). There were no significant difference within and between the placebo and the fish oil groups for weight reduction (3.37% and 4.35% respectively), fat mass reduction (8.95% and 9.76% respectively), or changes in inflammatory biomarkers and blood lipids apart from triglycerides, reduced by 27% in fish oil group (p < 0.05). For fish oil group there were significant correlations between leptin and weight loss (p = 0.01) and leptin and EPA and DHA (p < 0.05 for both).
Dietary LCn-3PUFA supplementation during a weight loss program does not appear to assist weight loss. Poor dietary compliance may be a contributing factor in accurate assessment of the role of these fatty acids in weight loss.
肥胖与炎症和代谢异常水平升高有关，患胰岛素抵抗、2 型糖尿病、中风和心血管疾病的风险增加。有助于减肥的营养素也可能降低与肥胖相关的合并症的风险。
本研究旨在探讨 LCn-3PUFA 与低能量饮食相结合是否有助于减肥以及改善血脂和炎症介质。
一项双盲随机对照试验，分为两组平行。两组均进行为期 12 周的低能量饮食，一组每天服用 6×1g 胶囊单不饱和油（安慰剂）（n=18），另一组每天服用 6×1g 胶囊 LCn-3PUFA（鱼油）（n=17）。在基线和干预后采集空腹血样、人体测量学测量和 3 天饮食日记。
鱼油组血浆 EPA 和 DHA 水平增加了两倍（p<0.001）。安慰剂组和鱼油组的体重减轻（分别为 3.37%和 4.35%）、脂肪量减少（分别为 8.95%和 9.76%）或炎症生物标志物和血脂变化均无显著差异，除甘油三酯外，鱼油组降低了 27%（p<0.05）。对于鱼油组，瘦素与体重减轻呈显著相关（p=0.01），瘦素与 EPA 和 DHA 也呈显著相关（p<0.05）。
在减肥计划中补充膳食 LCn-3PUFA 似乎无助于减肥。饮食依从性差可能是准确评估这些脂肪酸在减肥中的作用的一个因素。
